amador bioscience-png
Blog_Hero_FullWidth_1600x540@2x

News

Jan 22, 2024

Welcome back from JPM2024 Welcome back from JPM2024 At Amador, we’re committed to leveraging our global network and expert teams to bring innovative drugs to the world stage. Let’s keep up ...

Nov 20, 2023

Exciting Discussion at NYSE: Shaping the Future of Biotechnology Exciting Discussion at NYSE: Shaping the Future of Biotechnology Earlier this year, the Amador team had the incredible opportunity to engage in a dynamic discussion with the NYSE Cassandra Seier, Head of ...

Nov 10, 2023

WARNING: Amador's Official Recruitment WARNING: Amador's Official Recruitment Someone impersonating Amador is trying to commit recruitment scams on the internet. We don't want anyone to fall for this scam. Therefore, ...

May 10, 2023

NYSE Celebrates 5 Years of Amador NYSE Celebrates 5 Years of Amador Exciting news! Last month, we marked our 5th anniversary, and the New York Stock Exchange joined in the celebration by showcasing us on the ...

May 5, 2023

Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology Amador Bioscience appoints Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology to accelerate ...

Mar 7, 2023

Dr. Lorin K. Roskos, Biopharmaceutical Leader and Executive, Joins Amador Bioscience’s Board of Directors Dr. Lorin K. Roskos, Biopharmaceutical Leader and Executive, Joins Amador Bioscience’s Board of Directors Dr. Lorin K Roskos, biopharmaceutical leader and executive, joins Amador Bioscience’s board of directors.

Nov 2, 2022

Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland Celebrating its strategic milestone opening in an emerging biotech hub, Amador welcomed many distinguished guests to its new facilities in ...

Oct 28, 2022

Amador Bioscience and BIOMED Finalize Collaboration Amador Bioscience and BIOMED Finalize Collaboration Amador Bioscience and BIOMED announce collaboration to support clinical studies with omics-based biomarker discovery capabilities.

Oct 21, 2022

Amador Bioscience Appoints Dr. Howard Yuwen as Senior Vice President of Global Regulatory Affairs Amador Bioscience Appoints Dr. Howard Yuwen as Senior Vice President of Global Regulatory Affairs Amador Bioscience, announces the appointment of Dr. Howard Yuwen to Senior Vice President of Global Regulatory Affairs.

Sep 21, 2022

More Than Four Million Euros for Third-phase Expansion of Netherland-based BioVille More Than Four Million Euros for Third-phase Expansion of Netherland-based BioVille Amador Bioscience announces its arrival at BioVille, an incubator for life science organizations that recently received funding to expand ...

Sep 12, 2022

Amador Bioscience and Ann Arbor Pharmacometrics Group Further Align to Take End-to-End Drug Development Into the Future Amador Bioscience and Ann Arbor Pharmacometrics Group Further Align to Take End-to-End Drug Development Into the Future Ann Arbor Pharmacometrics Group (A2PG) joined forces with Amador Bioscience to strengthen its global leadership in clinical pharmacology.

Mar 10, 2022

Amador Bioscience Establishes Clinical Division in Hangzhou Amador Bioscience Establishes Clinical Division in Hangzhou On March 10, 2022, we announced the establishment of a new clinical business unit in Hangzhou. Patrick Hu, MD, was appointed as the chief ...

Jan 10, 2022

Dr. Meina Liang Joins Amador Bioscience as Chief Technology Officer Dr. Meina Liang Joins Amador Bioscience as Chief Technology Officer Amador Bioscience announced the appointment of Dr. Meina Liang, PhD, a world-renowned expert in innovative drug R&D and bioanalysis, as ...

Dec 31, 2021

Translational Science and Clinical Pharmacology CRO, Amador Bioscience, Announces the Completion of Over $60 Million in Series B+ Financing Translational Science and Clinical Pharmacology CRO, Amador Bioscience, Announces the Completion of Over $60 Million in Series B+ Financing The new round of financing was led by Heyu Capital (MSA), and the existing shareholders Sequoia China, Hillhouse Ventures, and Kaifeng ...

Dec 24, 2021

Amador Bioscience Acquires Ann Arbor Pharmacometrics Group (A2PG) Amador Bioscience Acquires Ann Arbor Pharmacometrics Group (A2PG) Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed the acquisition of ...

Nov 28, 2021

Amador Bioscience Expands to Belgium Amador Bioscience Expands to Belgium The Biopharmaceutical Ecosystem Development Seminar goal was to discuss how to promote the development of new drug research and growth of ...

Nov 4, 2021

Strategic Cooperation Agreement Between Amador Bioscience and Belgian Government Strategic Cooperation Agreement Between Amador Bioscience and Belgian Government Amador Biotech signed a strategic cooperation with the Belgian government. Tom Vandeput, Deputy Governor of Limburg Province in Belgium, ...

Don't miss our latest news!

Join our mailing list.